Iron Deficiency and Fibroblast Growth Factor 23 Regulation in Chronic Kidney Disease and Heart Failure

Trial Profile

Iron Deficiency and Fibroblast Growth Factor 23 Regulation in Chronic Kidney Disease and Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Iron sucrose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms INDIGO
  • Most Recent Events

    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top